Add Presentation to Slide Tray Presentation:
Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Clinical Questions Addressed by the CER (1 of 2)
Despite being widely used, there are still unanswered questions about the effectiveness and safety of DMARDs used to treat JIA, including:
- What is the effectiveness of DMARDs when compared with conventional anti-inflammatory/anti-immune treatments?
- What is the comparative effectiveness of DMARDs, both within a drug class and between drug classes?
- What is the long-term safety of the DMARDs? Drugs in both categories carry safety warnings. Anti–TNF-α DMARDs are associated with increased risk of cancer (lymphoma) and serious infections.
Keywords: Juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatic arthritis | JCA | juvenile chronic arthritis | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | biologic | nonbiologic | non-biologic | tumor necrosis factor-alpha | TNF-alpha | TNF-a
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.